Cargando…

Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort

INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predi...

Descripción completa

Detalles Bibliográficos
Autores principales: Alexander, Suceena, Varughese, Santosh, Franklin, Rajanbabu, Rebekah, Grace, Roy, Sanjeet, Yusuf, Sabina, Thomas, Athul, Eapen, Jeethu Joseph, John, Elenjickal Elias, Valson, Anna T., David, Vinoi George, Daha, Mohamed R., Feehally, John, Barratt, Jonathan, John, George T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820995/
https://www.ncbi.nlm.nih.gov/pubmed/35155869
http://dx.doi.org/10.1016/j.ekir.2021.11.012
_version_ 1784646325857419264
author Alexander, Suceena
Varughese, Santosh
Franklin, Rajanbabu
Rebekah, Grace
Roy, Sanjeet
Yusuf, Sabina
Thomas, Athul
Eapen, Jeethu Joseph
John, Elenjickal Elias
Valson, Anna T.
David, Vinoi George
Daha, Mohamed R.
Feehally, John
Barratt, Jonathan
John, George T.
author_facet Alexander, Suceena
Varughese, Santosh
Franklin, Rajanbabu
Rebekah, Grace
Roy, Sanjeet
Yusuf, Sabina
Thomas, Athul
Eapen, Jeethu Joseph
John, Elenjickal Elias
Valson, Anna T.
David, Vinoi George
Daha, Mohamed R.
Feehally, John
Barratt, Jonathan
John, George T.
author_sort Alexander, Suceena
collection PubMed
description INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression. METHODS: A total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids. RESULTS: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m(2) decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m(2), commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. The receiver operating characteristic curve of average annual decline in eGFR ≥ 5 ml/min per 1.73 m(2) had 86% sensitivity and 89% specificity for CO in 3 years and had good discrimination from 1 year onwards (area under the curve 0.8, SE 0.04, 95% CI 0.7–0.9, P < 0.0001). The significant predictors of CO by Cox proportional-hazards model were as follows: baseline MEST-T2 score (hazard ratio [HR] 3.3, 95% CI 1.7–6.5, P < 0.001), along with 24-hour urine protein level ≥ 1 g/d (HR 2.1, 95% CI 1.1–3.9, P = 0.02), eGFR < 60 ml/min per 1.73 m(2) (HR 2.9, 95% CI 1.1–7.6, P = 0.03), and rate of eGFR decline ≥ 5 ml/min per 1.73 m(2)/yr (HR 2.7, 95% CI 1.6–4.8, P < 0.001) all measured at 6 months. Mortality was 11 of 195 (5.6%). CONCLUSION: We identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m(2) annual fall in eGFR after kidney biopsy as important predictors for composite outcome in addition to baseline histology.
format Online
Article
Text
id pubmed-8820995
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-88209952022-02-11 Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort Alexander, Suceena Varughese, Santosh Franklin, Rajanbabu Rebekah, Grace Roy, Sanjeet Yusuf, Sabina Thomas, Athul Eapen, Jeethu Joseph John, Elenjickal Elias Valson, Anna T. David, Vinoi George Daha, Mohamed R. Feehally, John Barratt, Jonathan John, George T. Kidney Int Rep Regional Report INTRODUCTION: Glomerular Research And Clinical Experiments—IgA Nephropathy in Indians (GRACE-IgANI) is the first prospective South Asian IgA nephropathy (IgAN) cohort with prespecified objectives, protocolized longitudinal follow-up, and extensive biosample collection. The baseline risk scores predicted high risk of kidney disease progression. METHODS: A total of 195 of 201 patients (97%) completed 3-year follow-up in September 2020. All patients received optimized supportive care, and those at high risk of progression were offered systemic corticosteroids. RESULTS: A total of 76 patients (76 of 193, 39.4%) had rapid progression in 3 years (≥5 ml/min per 1.73 m(2) decline in estimated glomerular filtration rate [eGFR] per year). A total of 72 patients (72 of 195, 36.9%) experienced the composite outcome (CO), defined as ≥50% fall in eGFR, eGFR < 15 ml/min per 1.73 m(2), commenced kidney replacement therapy or death, in 3 years. At each scheduled follow-up, achievement of proteinuria level < 1 g/d significantly delayed the time to the CO. The receiver operating characteristic curve of average annual decline in eGFR ≥ 5 ml/min per 1.73 m(2) had 86% sensitivity and 89% specificity for CO in 3 years and had good discrimination from 1 year onwards (area under the curve 0.8, SE 0.04, 95% CI 0.7–0.9, P < 0.0001). The significant predictors of CO by Cox proportional-hazards model were as follows: baseline MEST-T2 score (hazard ratio [HR] 3.3, 95% CI 1.7–6.5, P < 0.001), along with 24-hour urine protein level ≥ 1 g/d (HR 2.1, 95% CI 1.1–3.9, P = 0.02), eGFR < 60 ml/min per 1.73 m(2) (HR 2.9, 95% CI 1.1–7.6, P = 0.03), and rate of eGFR decline ≥ 5 ml/min per 1.73 m(2)/yr (HR 2.7, 95% CI 1.6–4.8, P < 0.001) all measured at 6 months. Mortality was 11 of 195 (5.6%). CONCLUSION: We identified longitudinal clinical variables measured at 6 months and ≥5 ml/min per 1.73 m(2) annual fall in eGFR after kidney biopsy as important predictors for composite outcome in addition to baseline histology. Elsevier 2021-11-24 /pmc/articles/PMC8820995/ /pubmed/35155869 http://dx.doi.org/10.1016/j.ekir.2021.11.012 Text en © 2021 International Society of Nephrology. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Regional Report
Alexander, Suceena
Varughese, Santosh
Franklin, Rajanbabu
Rebekah, Grace
Roy, Sanjeet
Yusuf, Sabina
Thomas, Athul
Eapen, Jeethu Joseph
John, Elenjickal Elias
Valson, Anna T.
David, Vinoi George
Daha, Mohamed R.
Feehally, John
Barratt, Jonathan
John, George T.
Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title_full Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title_fullStr Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title_full_unstemmed Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title_short Three-Year Clinical Outcomes of the First South Asian Prospective Longitudinal Observational IgA Nephropathy Cohort
title_sort three-year clinical outcomes of the first south asian prospective longitudinal observational iga nephropathy cohort
topic Regional Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8820995/
https://www.ncbi.nlm.nih.gov/pubmed/35155869
http://dx.doi.org/10.1016/j.ekir.2021.11.012
work_keys_str_mv AT alexandersuceena threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT varughesesantosh threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT franklinrajanbabu threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT rebekahgrace threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT roysanjeet threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT yusufsabina threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT thomasathul threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT eapenjeethujoseph threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT johnelenjickalelias threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT valsonannat threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT davidvinoigeorge threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT dahamohamedr threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT feehallyjohn threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT barrattjonathan threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort
AT johngeorget threeyearclinicaloutcomesofthefirstsouthasianprospectivelongitudinalobservationaliganephropathycohort